Lv21
150 积分 2021-06-24 加入
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma
6天前
已完结
Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
20天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已关闭
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: combination of HX008 and niraparib in GErm-line-mutAted metastatic breast cancer
2个月前
已完结
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck: A Multicenter, Phase IIa Trial
3个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
3个月前
已完结
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
3个月前
已完结
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
4个月前
已完结
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
4个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
4个月前
已完结
皖公网安备34019202002308
